Viking Therapeutics
$29.92
740
+$0.88+3.03% Monday 21:00
Statistics
Day High
30.25
Day Low
28.55
52W High
43.15
52W Low
18.92
Volume
2,493,910
Avg. Volume
3,213,057
Mkt Cap
3.38B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11FebExpected
Expected EPS
-0.896067
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-219.93MNet Income
Analyst Ratings
$102.20Average Price Target
The highest estimate is 125.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow VKTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Viking Therapeutics
VKTX
Mkt Cap4.3B
Gilead Sciences
GILD
Mkt Cap148.78B
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
AMGEN
AMGN
Mkt Cap160.66B
Astrazeneca
AZN
Mkt Cap256.58B
About
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Show more...
CEO
Dr. Brian Lian Ph.D.
Employees
45
Country
US
ISIN
US92686J1060
Listings
0 Comments
Share your thoughts
FAQ
What is Viking Therapeutics stock price today?▼
The current price of VKTX is $29.92 USD — it has increased by +3.03% in the past 24 hours. Watch Viking Therapeutics stock price performance more closely on the chart.
What is Viking Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Viking Therapeutics stocks are traded under the ticker VKTX.
Is Viking Therapeutics stock price growing?▼
VKTX stock has fallen by -4.71% compared to the previous week, the month change is a -15.53% fall, over the last year Viking Therapeutics has showed a -5.08% decrease.
What is Viking Therapeutics market cap?▼
Today Viking Therapeutics has the market capitalization of 3.38B
When is the next Viking Therapeutics earnings date?▼
Viking Therapeutics is going to release the next earnings report on February 11, 2026.
What were Viking Therapeutics earnings last quarter?▼
VKTX earnings for the last quarter are -0.81 USD per share, whereas the estimation was -0.71 USD resulting in a -14.16% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viking Therapeutics revenue for the last year?▼
Viking Therapeutics revenue for the last year amounts to 0 USD.
What is Viking Therapeutics net income for the last year?▼
VKTX net income for the last year is -219.93M USD.
How many employees does Viking Therapeutics have?▼
As of February 03, 2026, the company has 45 employees.
In which sector is Viking Therapeutics located?▼
Viking Therapeutics operates in the Health Care sector.
When did Viking Therapeutics complete a stock split?▼
Viking Therapeutics has not had any recent stock splits.
Where is Viking Therapeutics headquartered?▼
Viking Therapeutics is headquartered in San Diego, US.